Radioactive iodine (131I) effects on male fertility

被引:23
作者
Ceccarelli, Claudia [1 ]
Canale, Domenico [1 ]
Vitti, Paolo [1 ]
机构
[1] Univ Pisa, Med Sch & Hosp, Dept Endocrinol, I-56123 Pisa, Italy
关键词
hyperthyroidism; male fertility; radioiodine-131; therapy; testis; thyroid cancer;
D O I
10.1097/MOU.0b013e32831367b3
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Radiometabolic therapy with radioactive iodine (I-131) is the standard treatment for differentiated thyroid cancer and is also currently the treatment of choice for Graves' disease in the United States. and in most countries. Men younger than 40 years of age represent about 10% of all radiometabolic treatments. Thus, the question arises whether I-131 therapy is able to induce a damage to the fertility potential. Recent findings The different effects caused by I-131 therapy employed in cancer and hyperthyroid patients are reviewed. Most articles about the first category of patients show a damage to the germinal epithelium directly related to the cumulative dose delivered. Although the small amounts used in hyperthyroidism are usually well tolerated in terms of sterility risk, the impairment caused by hyperthyroidism per se is probably higher than that caused by I-131 treatment. Summary Young cancer patients, particularly those with node or lung metastases, who will probably undergo repeated treatments should be aware of the potential risks to their fertility. An evaluation of testicular function is thus advisable. When an impairment of fertility potential is already present, the option of freezing semen should be considered. The available studies concerning I-131 therapy in hyperthyroidism suggest that this treatment does not cause a worsening of semen analysis but an amelioration in affected patients.
引用
收藏
页码:598 / 601
页数:4
相关论文
共 33 条
[1]   Hypothalamic-pituitary-testicular axis and seminal parameters in hyperthyroid males [J].
Abalovich, M ;
Levalle, O ;
Hermes, R ;
Scaglia, H ;
Aranda, C ;
Zylbersztein, C ;
Oneto, A ;
Aquilano, D ;
Gutierrez, S .
THYROID, 1999, 9 (09) :857-863
[2]   The spectrum of thyroid disorders in an iodine-deficient community: The Pescopagano survey [J].
Aghini-Lombardi, F ;
Antonangeli, L ;
Martino, E ;
Vitti, P ;
Maccherini, D ;
Leoli, F ;
Rago, T ;
Grasso, L ;
Valeriano, R ;
Balestrieri, A ;
Pinchera, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (02) :561-566
[3]   Serum inhibin B and follicle-stimulating hormone levels as tools in the evaluation of infertile men:: Significance of adequate reference values from proven fertile men [J].
Andersson, AM ;
Petersen, JH ;
Jorgensen, N ;
Jensen, TK ;
Skakkebæk, NE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (06) :2873-2879
[4]   Serum TSH and total T4 in the United States population and their association with participant characteristics:: National Health and Nutrition Examination Survey (NHANES 1999-2002) [J].
Aoki, Yutaka ;
Belin, Ruth M. ;
Clickner, Robert ;
Jeffries, Rebecca ;
Phillips, Linda ;
Mahaffey, Kathryn R. .
THYROID, 2007, 17 (12) :1211-1223
[5]   Conception after iodine-131 therapy for differentiated thyroid cancer [J].
Ayala, C ;
Navarro, E ;
Rodriguez, JR ;
Silva, H ;
Venegas, E ;
Astorga, R .
THYROID, 1998, 8 (11) :1009-1011
[6]  
Baker H W, 1976, Recent Prog Horm Res, V32, P429
[7]  
Baskin HJ., 2002, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, V8, P457, DOI DOI 10.4158/1934-2403-8.6.457
[8]  
BUSHBERG JT, 2002, ESSENTIAL PHYS MED I, P831
[9]  
CASARA D, 1993, EUR J NUCL MED, V20, P192
[10]  
Ceccarelli C, 1999, J NUCL MED, V40, P1716